Review Article
Cysteinyl Leukotriene Receptor-1 Antagonists as Modulators of Innate Immune Cell Function
Table 2
Cysteinyl leukotriene receptor-1-independent anti-inflammatory activities of montelukast, pranlukast, and zafirlukast.
| Anti-inflammatory activity | Cell type | Antagonist |
| ↓ Activity of 5-lipoxygenase [26, 30, 31]* | Neutrophils, monocytes/macrophages | Montelukast and zafirlukast |
| Inhibition of cyclic nucleotide phosphodiesterases [26, 32] | Neutrophils (also described in airway smooth muscle cells) | Montelukast |
| ↓ Activity of NFκB [29, 34–36] | Monocytes/macrophages (also described in T cells, epithelial cells and endothelial cells) | Montelukast and pranlukast |
| Inhibition of microsomal prostaglandin E synthase-1 [37] | Monocytes/macrophages | Montelukast, pranlukast, and zafirlukast |
| ↓ Eosinophil adhesion and migration [38, 39] | Eosinophils | Montelukast |
| ↑ Activity of AMP-activated protein kinase [43] | Relevance to cells of the innate immune system not yet established | Pranlukast |
| Antagonism of P2Y receptors [31] | Monocytes/macrophages | Montelukast and zafirlukast |
|
|
denotes relevant references cited in the text.
|